1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Latecomer Brigatinib Looking Good In First-Line NSCLC Head-To-head

 
• By Ian Haydock

Takeda's ALK inhibitor meets primary endpoint in interim analysis from critical first-line lung cancer head-to-head study, helping validate Ariad acquisition, but will be a relative class latecomer to the setting.  

Cancer cells on scientific background.3d illustration
PROMISING RESULTS FOR BRIGATINIB IN FIRST-LINE NSCLC • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.'s oral anaplastic lymphoma kinase (ALK) inhibitor brigatinib has shown progression-free survival (PFS) benefits over close rival crizotinib in the first interim analysis from an ongoing head-to-head trial in the commercially important first-line lung cancer setting.

While the Japanese firm did not disclose details of the top-line findings, it said the first pre-specified interim analysis from the global Phase III ALTA-1L trial showed a statistically significant improvement against the primary endpoint of PFS

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas